TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22805100
Drug: 4 IT
Normalized name: IT-139
DrugBank: IT-139 (DB17145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 IT doses for 14 days of 40 mg/ml methylprednisolone (129 patients)
Study: 12432178
Drug: Bovine colostrum
Normalized name: Bovine Colostrum
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine colostrum (BC; 60 g day-1)
Study: 12432178
Drug: Concentrated whey
Normalized name: whey protein hydrolysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentrated whey protein powder (WP; 60 g day-1)
Study: 6744778
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg HCTZ/amiloride 2.5 mg
Study: 6744778
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg HCTZ alone
Study: 6744778
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg HCTZ/amiloride 2.5 mg (higher dose)
Study: 30702519
Drug: Daily protein-calorie
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily protein-calorie supplement and micronutrient supplement
Study: 30702519
Drug: Micronutrient supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrient supplement only
Study: 30201853
Drug: 48 g
Normalized name: GLYCERIN 3 g in 48 g CUTANEOUS OINTMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 48 g Casein Protein (CP)
Study: 30201853
Drug: 24 g
Normalized name: glucose 24 g/31 g oral gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 g Casein Protein (CP)
Study: 30201853
Drug: 24 g
Normalized name: glucose 24 g/31 g oral gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 g Whey Protein (WP)
Study: 30201853
Drug: 48 g
Normalized name: GLYCERIN 3 g in 48 g CUTANEOUS OINTMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 48 g Whey Protein (WP)
Study: 24650926
Drug: Aortic pressure-guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aortic pressure-guided treatment (active, n=23)
Study: 24650926
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (control, n=27)
Study: 24650926
Drug: Aortic pressure-guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aortic pressure-guided treatment (active)
Study: 17870636
Drug: 3-day oral
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-day oral quinine-clindamycin
Study: 12244905
Drug: Daily site
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily site care with povidone-iodine 10% solution and new sterile gauze (Group II)
Study: 12244905
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition administration
Study: 12244905
Drug: Coexisting malignancy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coexisting malignancy or diabetes mellitus, duration of catheter, antibiotics use
Study: 10416046
Drug: CoQ10 100
Normalized name: Walgreens CoQ10 100mg Softgel
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoQ10 100 mg bid
Study: 7580834
Drug: HGP‐30 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HGP‐30 vaccine (10 and 25 micrograms/kg)
Study: 7580834
Drug: HGP‐30 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HGP‐30 vaccine (50 and 100 micrograms/kg)
Study: 7580834
Drug: HGP‐30 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HGP‐30 vaccine
Study: 2164934
Drug: Ketoconazole tablets
Normalized name: Ketoconazole Tablets
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoconazole tablets every 8 hours for six doses
Study: 2164934
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol patch
Study: 2164934
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ketoconazole and transdermal estradiol
Study: 31422390
Drug: Dexamethasone plus
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone plus antibiotic
Study: 31422390
Drug: Antibiotic and
Normalized name: Triple Antibiotic And Pain Relief
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic and placebo (Control)
Study: 29525907
Drug: Intralesional injection
Normalized name: DEXAMETHASONE SODIUM PHOSPHATE 4 mg in 1 mL INTRALESIONAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional injection of 10 mg/ml triamcinolone (steroid)
Study: 29525907
Drug: Intralesional injection
Normalized name: DEXAMETHASONE SODIUM PHOSPHATE 4 mg in 1 mL INTRALESIONAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional injection of 1 ml autologous platelet-rich plasma (PRP)
Study: 29525907
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (PRP and ILS)
Study: 26574953
Drug: Dutasteride (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride (0.5 mg od)
Study: 26574953
Drug: Finasteride (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride (5 mg od)
Study: 24964392
Drug: Darunavir/cobicistat fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darunavir/cobicistat fixed-dose combination (FDC) 800 mg/150 mg
Study: 24964392
Drug: Darunavir (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darunavir (800 mg) and cobicistat (150 mg) as single agents
Study: 22368231
Drug: Rituximab (RTX)
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab (RTX) treatment with methotrexate after 1 g infusion on days 1 and 15
Study: 22368231
Drug: Rituximab (RTX)
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab (RTX) treatment in rheumatoid factor-positive patients
Study: 20022717
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy by mothers plus skin‐to‐skin care (Intervention Group)
Study: 17404083
Drug: Ketoconazole treatment
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoconazole treatment
Study: 16334808
Drug: Enprostil 25
Normalized name: enprostil
DrugBank: Enprostil (DB13824)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enprostil 25 microg b.i.d. and cimetidine 400 mg b.i.d. for 8 weeks
Study: 16334808
Drug: Cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 400 mg b.i.d. alone for 8 weeks
Study: 12494804
Drug: Bilateral ilioinguinal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral ilioinguinal nerve block with 15 ml x 2 of 0.25% bupivacaine
Study: 12494804
Drug: Subcutaneous 1
Normalized name: IgG, human subcutaneous 16 % Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous 1 mg kg‐1 of tramadol
Study: 2945420
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg nicorandil
Study: 20685043
Drug: 1mg IV
Normalized name: bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1mg IV cortisol infusion
Study: 15147434
Drug: Fluvastatin (40-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin (40-80 mg/day)
Study: 7694321
Drug: Mono-chemotherapy
Normalized name: tiotropium bromide mono
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mono-chemotherapy
Study: 23571496
Drug: Pegylated filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pegylated filgrastim 100 µg/kg
Study: 25820754
Drug: Filgrastim 5
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Filgrastim 5 µg/kg/day
Study: 20033901
Drug: Brief problem-solving
Normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief problem-solving treatment by primary care doctors (PST-PC)
Study: 16919061
Drug: Medication overuse
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medication overuse headache (MOH)
Study: 16919061
Drug: Triptan-induced medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptan-induced medication overuse headache (MOH)
Study: 15265052
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (3 sessions)
Study: 15265052
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (3 hyperbaric air treatments)
Study: 15265052
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (hyperbaric air treatments)
Study: 8331200
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 20 mg
Study: 8331200
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 40 mg
Study: 8331200
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 80 mg
Study: 8331200
Drug: Multiple dose
Normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dose administration of 40 mg/day for 5 days
Study: 8331200
Drug: Multiple dose
Normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dose administration of 80 mg/day for 5 days
Study: 8331200
Drug: Multiple dose
Normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dose administration of 160 mg/day for 5 days
Study: 31533818
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg intravenously every 3 weeks
Study: 28970147
Drug: Fructans (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fructans (0.5 g/kg; maximum, 19 g)
Study: 12492188
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg p.o. b.i.d. for 6 weeks
Study: 12492188
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules p.o. b.i.d. for 6 weeks
Study: 2695806
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg telenzepine once daily
Study: 2695806
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg telenzepine once daily
Study: 2695806
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg telenzepine once daily
Study: 2695806
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg and 3 mg telenzepine
Study: 11986476
Drug: Long-course antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-course antibiotic therapy (7-14 days)
Study: 30952565
Drug: Integrated care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated care centres providing HIV testing, prevention, and treatment services.
Study: 28592250
Drug: Mass Testing
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mass Testing and Treatment (MTaT) approach
Study: 10517908
Drug: 2% diltiazem
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% diltiazem gel
Study: 19768381
Drug: Sequential intravenous/oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential intravenous/oral moxifloxacin, 400 mg once daily for 7-21 days
Study: 19768381
Drug: Intravenous amoxicillin/clavulanate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous amoxicillin/clavulanate, 1,000 mg/200 mg three times daily followed by oral amoxicillin/clavulanate, 500 mg/125 mg three times daily for 7-21 days
Study: 16229991
Drug: Sequential intravenous/oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential intravenous/oral moxifloxacin
Study: 19768381
Drug: Intravenous amoxicillin/clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous amoxicillin/clavulanate followed by oral amoxicillin/clavulanate
Study: 18268075
Drug: Ramipril (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (15 mg/day)
Study: 9692107
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids treatment for 3 years
Study: 2848902
Drug: Human-rhesus reassortant
Normalized name: human-bovine reassortant rotavirus strain G4 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human-rhesus reassortant rotavirus vaccines (serotypes 1, 2, or 4)
Study: 2848902
Drug: Human-rhesus reassortant
Normalized name: human-bovine reassortant rotavirus strain G4 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human-rhesus reassortant rotavirus vaccines (serotype 2)
Study: 2848902
Drug: Human-rhesus reassortant
Normalized name: human-bovine reassortant rotavirus strain G4 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human-rhesus reassortant rotavirus vaccines
Study: 21145807
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg ribavirin/day
Study: 21145807
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg ribavirin/day
Study: 21145807
Drug: peginterferon alfa-2a/ribavirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: peginterferon alfa-2a/ribavirin treatment
Study: 15215811
Drug: Pravastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (20 to 40 mg)
Study: 9292674
Drug: Subconjunctival cefuroxime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subconjunctival cefuroxime not administered (n=9)
Study: 3111689
Drug: Elantan Long
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elantan Long (50 mg IS 5‐MN) daily for 12 months
Study: 27821027
Drug: Weekly intralesional
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly intralesional triamcinolone injections
Study: 27821027
Drug: Biweekly intralesional
Normalized name: Biweekly Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biweekly intralesional triamcinolone injections
Study: 22327761
Drug: Xylitol (chewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylitol (chewing gum for mothers and chewable tablets for children, 3 times a day for 3 months)
Study: 19404314
Drug: Nebivolol 20
Normalized name: nebivolol 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol 20 mg
Study: 20162736
Drug: Nebivolol 5-20
Normalized name: nebivolol 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol 5-20 mg
Study: 12523328
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g rectal paracetamol
Study: 12523328
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg x kg(‐1) rectal paracetamol
Study: 1535579
Drug: Clarithromycin 250
Normalized name: clarithromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 250 mg
Study: 9798808
Drug: Amoxycillin 1
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin 1 g
Study: 7900626
Drug: Sotalol 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol 1.0 mg/kg
Study: 7900626
Drug: Sotalol 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol 1.5 mg/kg
Study: 7900626
Drug: Sotalol 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol 1.5 mg/kg (open-label phase)
Study: 7900626
Drug: Sotalol 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol 1.0 mg/kg (AF group)
Study: 7900626
Drug: Sotalol 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol 1.5 mg/kg (AF group)
Study: 7900626
Drug: Sotalol 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol 1.5 mg/kg (open-label phase, AF group)
Study: 2527133
Drug: Multiple daily
Normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple daily insulin injections (three preprandial injections of short‐acting insulin (NovoPen) and once daily, bedtime extended‐acting insulin)
Study: 2527678
Drug: Multiple daily
Normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple daily insulin injections (NovoPen)
Study: 781234
Drug: Fenoprofen, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoprofen, 200 to 600 mg every six hours
Study: 781234
Drug: Aspirin, 325
Normalized name: Aspirin, 325 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin, 325 to 975 mg every six hours
Study: 31647605
Drug: Intravenous iscalimab
Normalized name: Iscalimab
DrugBank: Iscalimab (DB15260)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iscalimab (0.03, 0.1, 0.3, 1, or 3 mg/kg)
Study: 31647605
Drug: Intravenous iscalimab
Normalized name: Iscalimab
DrugBank: Iscalimab (DB15260)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iscalimab (10 or 30 mg/kg)
Study: 31647605
Drug: Intravenous iscalimab
Normalized name: Iscalimab
DrugBank: Iscalimab (DB15260)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iscalimab (3 mg/kg)
Study: 31647605
Drug: Intravenous iscalimab
Normalized name: Iscalimab
DrugBank: Iscalimab (DB15260)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iscalimab
Study: 29800080
Drug: Behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral treatment (weekly lifestyle counseling and meal replacement diet)
Study: 26044516
Drug: Probiotic group
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic group (2 g of powder containing 5 × 10^9 cfu of L. curvatus HY7601 and 5 × 10^9 cfu of L. plantarum KY1032 daily)
Study: 16960523
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg of soybean‐derived phosphatidylserine (S‐PtdSer), administered daily for 7 days prior to exercise and for 2 days following exercise
Study: 29652792
Drug: Blue mussel
Normalized name: Blue mussel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blue mussel diet (75 g blue mussels, five days a week)
Study: 29652792
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet (75 g meat, five days a week)
Study: 27256357
Drug: ebselen (3600
Approvals — FDA: no, EMA: no, PMDA: no
Description: ebselen (3600 mg over 24 h)
Study: 25518523
Drug: L-carnitine (Elkar,
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (Elkar, PikFarma)
Study: 22858387
Drug: Sertraline (50-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50-200 mg/day for 4 months)
Study: 21184675
Drug: TPN with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPN with daily glutamine supplement of 0.35 g/kg
Study: 18702333
Drug: peg‐IFN‐alpha/RBV treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: peg‐IFN‐alpha/RBV treatment (n = 18 with 2a, n = 9 with 2b)
Study: 18702333
Drug: peg‐IFN‐alpha/RBV treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: peg‐IFN‐alpha/RBV treatment
Study: 12733733
Drug: Alendronate, 10
Normalized name: Alendronate, 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate, 10 mg/day plus calcium carbonate (600 mg daily)
Study: 12733733
Drug: Simple vitamin
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple vitamin D (ergocalciferol, 30,000 IU weekly) plus calcium carbonate (600 mg daily)
Study: 11642080
Drug: Amlodipine (5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5-10 mg once a day)
Study: 10100105
Drug: Perindopril (4-8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (4-8 mg once a day)
Study: 1725545
Drug: Diltiazem controlled-release
Normalized name: diltiazem Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem controlled-release (CR) 120 mg b.i.d.
Study: 6861770
Drug: Metoprolol 100
Normalized name: metoprolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 100 mg b.i.d.
Study: 6401458
Drug: Concurrent hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent hormone treatment and cytotoxic chemotherapy
Study: 6401458
Drug: Sequential hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential hormone treatment and cytotoxic chemotherapy
Study: 6401458
Drug: Sequential hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential hormone treatment for postmenopausal women in the low-risk category
Study: 26897450
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (ST) for anxiety alleviation with anxiolytics
Study: 24814272
Drug: Autologous periorbital
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous periorbital fat injections
Study: 7664861
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide (80 micrograms) and sodium cromoglycate (20 mg) combined
Study: 10575337
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate (20 mg)
Study: 2708725
Drug: L-tryptophan supplementation
Normalized name: L-TRYPTOPHAN
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-tryptophan supplementation and dietary manipulation
Study: 935836
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets for 4-6 months (Control group)
Study: 22998340
Drug: Sugar-free, artificially
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar-free, artificially sweetened beverage (250 ml per day)
Study: 22998340
Drug: Sugar-containing beverage
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar-containing beverage (250 ml per day providing 104 kcal)
Study: 20634176
Drug: Colesevelam (3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colesevelam (3.75 g/d)
Study: 18250617
Drug: Ghrelin administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ghrelin administration (1 microg/kg)
Study: 11871738
Drug: Standard amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard amino acid solution (Vintène) for 10 days (Control group)